Researchers from the Keck School of Medicine of USC have developed a new type of chimeric antigen receptor (CAR) T cell that ...

STEM-engineered CAR T cells performed as well as or better against cancer cells than did FDA-approved CAR T cells and kept their cancer-fighting abilities for longer.

A small group of patients with an otherwise incurable form of T‑cell leukemia have seen their cancer driven into remission by ...

Researchers at The University of Texas MD Anderson Cancer Center have characterized the complex microenvironment in ...

Reducing calorie intake helps cancer-fighting immune cells do their jobs more effectively, reports a study by Van Andel ...

Chimeric antigen receptor (CAR) T-cell therapy can cure certain types of blood cancer, but cost and a general lack of ...

A cutting-edge base-edited CAR T-cell therapy is opening a revolutionary new frontier for patients battling aggressive T-cell ...

A cutting-edge therapy using base-edited immune cells is offering a major breakthrough for patients with one of the toughest ...

A therapy that would once have been considered a feat of science fiction has reversed aggressive and incurable blood cancers ...

Acute myeloid leukemia (AML) cells under the microscope, in purple. There is a serious need for finding better ways to treat AML that comes back after initial treatment. Chimeric antigen receptor (CAR ...

Patients who receive T-cell redirecting therapies are typically hospitalized for several days after treatment to watch for ...

USC researchers have developed a new type of chimeric antigen receptor (CAR) T cell that elicits a more controlled immune response to cancer in mice—effectively killing cancer cells, including those ...